Research programme: antiarrhythmic therapies - Numerate
Latest Information Update: 28 Sep 2023
At a glance
- Originator Numerate
- Class Antiarrhythmics; Heart failure therapies; Small molecules
- Mechanism of Action Sodium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Arrhythmias
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Arrhythmias in USA (PO)
- 08 Aug 2019 Early research results in arrhythmias were released by Numerate
- 07 Aug 2019 Numerate receives SBIR Phase II grant from National Heart, Lung, and Blood Institute for the development of small molecules in Arrhythmias